These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 32534033)

  • 21. Effects of linaclotide in patients with irritable bowel syndrome with constipation or chronic constipation: a meta-analysis.
    Videlock EJ; Cheng V; Cremonini F
    Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1084-1092.e3; quiz e68. PubMed ID: 23644388
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRP4 Modulation of the Guanylate Cyclase-C/cGMP Pathway: Effects on Linaclotide-Induced Electrolyte Secretion and cGMP Efflux.
    Tchernychev B; Ge P; Kessler MM; Solinga RM; Wachtel D; Tobin JV; Thomas SR; Lunte CE; Fretzen A; Hannig G; Bryant AP; Kurtz CB; Currie MG; Silos-Santiago I
    J Pharmacol Exp Ther; 2015 Oct; 355(1):48-56. PubMed ID: 26216942
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Linaclotide, novel therapy for the treatment of chronic idiopathic constipation and constipation-predominant irritable bowel syndrome.
    Vazquez-Roque MI; Bouras EP
    Adv Ther; 2013 Mar; 30(3):203-11. PubMed ID: 23436110
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Linaclotide: A new drug for the treatment of chronic constipation and irritable bowel syndrome with constipation.
    Corsetti M; Tack J
    United European Gastroenterol J; 2013 Feb; 1(1):7-20. PubMed ID: 24917937
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Randomised clinical trials: linaclotide phase 3 studies in IBS-C - a prespecified further analysis based on European Medicines Agency-specified endpoints.
    Quigley EM; Tack J; Chey WD; Rao SS; Fortea J; Falques M; Diaz C; Shiff SJ; Currie MG; Johnston JM
    Aliment Pharmacol Ther; 2013 Jan; 37(1):49-61. PubMed ID: 23116208
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The Use of Linaclotide in Children with Functional Constipation or Irritable Bowel Syndrome: A Retrospective Chart Review.
    Baaleman DF; Gupta S; Benninga MA; Bali N; Vaz KH; Yacob D; Di Lorenzo C; Lu PL
    Paediatr Drugs; 2021 May; 23(3):307-314. PubMed ID: 33876403
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Linaclotide for constipation-predominant IBS.
    Drug Ther Bull; 2013 Nov; 51(11):129-32. PubMed ID: 24227771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linaclotide activates guanylate cyclase-C/cGMP/protein kinase-II-dependent trafficking of CFTR in the intestine.
    Ahsan MK; Tchernychev B; Kessler MM; Solinga RM; Arthur D; Linde CI; Silos-Santiago I; Hannig G; Ameen NA
    Physiol Rep; 2017 Jun; 5(11):. PubMed ID: 28592587
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The use of novel promotility and prosecretory agents for the treatment of chronic idiopathic constipation and irritable bowel syndrome with constipation.
    Gale JD
    Adv Ther; 2009 May; 26(5):519-30. PubMed ID: 19444393
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicentre, non-interventional study of the efficacy and tolerability of linaclotide in the treatment of irritable bowel syndrome with constipation in primary, secondary and tertiary centres: the Alpine study.
    Pohl D; Fried M; Lawrance D; Beck E; Hammer HF
    BMJ Open; 2019 Dec; 9(12):e025627. PubMed ID: 31892640
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Linaclotide, a synthetic guanylate cyclase C agonist, for the treatment of functional gastrointestinal disorders associated with constipation.
    Vazquez Roque M; Camilleri M
    Expert Rev Gastroenterol Hepatol; 2011 Jun; 5(3):301-10. PubMed ID: 21651347
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Linaclotide for irritable bowel syndrome with constipation: a 26-week, randomized, double-blind, placebo-controlled trial to evaluate efficacy and safety.
    Chey WD; Lembo AJ; Lavins BJ; Shiff SJ; Kurtz CB; Currie MG; MacDougall JE; Jia XD; Shao JZ; Fitch DA; Baird MJ; Schneier HA; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1702-12. PubMed ID: 22986437
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Determining an optimal dose of linaclotide for use in Japanese patients with irritable bowel syndrome with constipation: A phase II randomized, double-blind, placebo-controlled study.
    Fukudo S; Nakajima A; Fujiyama Y; Kosako M; Nakagawa A; Akiho H; Nakashima Y; Johnston JM; Miwa H
    Neurogastroenterol Motil; 2018 May; 30(5):e13275. PubMed ID: 29278278
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The pharmacokinetics, pharmacodynamics, clinical efficacy, safety and tolerability of linaclotide.
    Lee N; Wald A
    Expert Opin Drug Metab Toxicol; 2011 May; 7(5):651-9. PubMed ID: 21446888
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Linaclotide is a potent and selective guanylate cyclase C agonist that elicits pharmacological effects locally in the gastrointestinal tract.
    Bryant AP; Busby RW; Bartolini WP; Cordero EA; Hannig G; Kessler MM; Pierce CM; Solinga RM; Tobin JV; Mahajan-Miklos S; Cohen MB; Kurtz CB; Currie MG
    Life Sci; 2010 May; 86(19-20):760-5. PubMed ID: 20307554
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipation.
    Blackshaw LA; Brierley SM
    Expert Rev Gastroenterol Hepatol; 2013 Jul; 7(5 Suppl 1):15-9. PubMed ID: 23859756
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation.
    Rao S; Lembo AJ; Shiff SJ; Lavins BJ; Currie MG; Jia XD; Shi K; MacDougall JE; Shao JZ; Eng P; Fox SM; Schneier HA; Kurtz CB; Johnston JM
    Am J Gastroenterol; 2012 Nov; 107(11):1714-24; quiz p.1725. PubMed ID: 22986440
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A randomized controlled and long-term linaclotide study of irritable bowel syndrome with constipation patients in Japan.
    Fukudo S; Miwa H; Nakajima A; Haruma K; Kosako M; Nakagawa A; Akiho H; Yamaguchi Y; Johnston JM; Currie M; Kinoshita Y
    Neurogastroenterol Motil; 2018 Dec; 30(12):e13444. PubMed ID: 30136447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic evaluation of linaclotide for the treatment of adult patients with irritable bowel syndrome with constipation in the United States.
    Huang H; Taylor DC; Carson RT; Sarocco P; Friedman M; Munsell M; Blum SI; Menzin J
    J Med Econ; 2015 Apr; 18(4):283-94. PubMed ID: 25333331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomised clinical trial: linaclotide vs placebo-a study of bi-directional gut and brain axis.
    Rao SSC; Xiang X; Yan Y; Rattanakovit K; Patcharatrakul T; Parr R; Ayyala D; Sharma A
    Aliment Pharmacol Ther; 2020 Jun; 51(12):1332-1341. PubMed ID: 32406112
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.